Annexin treats first NEXUS expanded-cohort patient in Germany
Annexin Pharmaceuticals treated the first NEXUS expanded-cohort patient in Germany with anti-VEGF followed by vanexin. The patient completed Day 15 follow-up with no adverse events.
Annexin Pharmaceuticals said the first patient in the NEXUS expanded cohort in Germany was treated with anti-VEGF followed by vanexin. The patient completed Day 15 follow-up with no adverse events. Up to three patients are planned in this cohort to assess safety and signals of effect.